Disability-adjusted Life Years in a Senegalese Cohort of Patients With Subarachnoid Hemorrhage
August 17, 2021 updated by: Association of Future African Neurosurgeons, Yaounde, Cameroon
Subarachnoid hemorrhage (SAH) is the extravasation of blood into the subarachnoid space from traumatic or nontraumatic origin.
There is a paucity of data on the burden of SAH in African countries.
In this study, we analyzed data from patients in the largest neurovascular center in Senegal to determine the sex- and age-adjusted burden of SAH in Senegal.
Study Overview
Status
Completed
Detailed Description
The Fann Teaching Hospital (Dakar, Senegal) institutional review board authorized this study.
Consent was obtained from adult patients and the parents/legal guardians of children.
Patient data were stored in a password-protected Excel spreadsheet, and this spreadsheet was stored on a hard drive.
Only the authors had access to the data.
Study Type
Observational
Enrollment (Actual)
388
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Dakar, Senegal
- Fann Teaching Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
We recruited 448 patients between 2011 and 2020.
However, 60 patients (13.4%) had incomplete records and were excluded from the analysis.
Herein we present the retrospective analysis of the 388 patients (86.6%) with complete records.
We received a median of 40.0 patients annually (IQR=51.5),
and a peak was observed in 2017 when 76 SAH patients were admitted at our institution.
Description
Inclusion Criteria:
- Sub-arachnoid Hemorrhage admission
Exclusion Criteria:
- Not admitted for sub-arachnoid hemorrhage
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Sub-arachnoid Hemorrhage Patients
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Disability Adjusted Life Years
Time Frame: 9 years
|
Mortality and Morbidity
|
9 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 26, 2021
Primary Completion (Actual)
August 16, 2021
Study Completion (Actual)
August 16, 2021
Study Registration Dates
First Submitted
August 17, 2021
First Submitted That Met QC Criteria
August 17, 2021
First Posted (Actual)
August 23, 2021
Study Record Updates
Last Update Posted (Actual)
August 23, 2021
Last Update Submitted That Met QC Criteria
August 17, 2021
Last Verified
August 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AFANSEN1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.